• BioInvent reported publication of new preclinical research on its TNFR2 antibodies BI-1808, BI-1910 in Cancer Research.
• Results were already presented via the peer-reviewed manuscript published on Aug. 20, 2026.
• Study supports BI-1808’s ability to trigger anti-tumor immune responses, including in tumors that typically resist checkpoint inhibitors.
• BI-1808 remains in ongoing Phase 2a trials, with early clinical signals described as encouraging across blood cancers and solid tumors.
• BI-1910 development is paused for prioritization, limiting near-term contribution versus the lead BI-1808 program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.